期刊
MOLECULAR THERAPY
卷 29, 期 2, 页码 505-520出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2020.10.023
关键词
-
资金
- Tessa Therapeutics
- National Heart, Lung, and Blood Institute of the National Institutes of Health [5T32HL09233217]
Immunotherapy using CAR-T cells and OVs has shown promise in cancer treatment, but the benefits as single-agent therapies are still limited to a subset of patients. Combinations of different targeted therapies may be needed to achieve efficient, durable responses against heterogeneous tumors and the microenvironment.
Immunotherapy has recently garnered success with the induction of clinical responses in tumors, which are traditionally associated with poor outcomes. Chimeric antigen receptor T (CAR-T) cells and oncolytic viruses (OVs) have emerged as promising cancer immunotherapy agents. Herein, we provide an overview of the current clinical status of CAR-T cell and OV therapies. While preclinical studies have demonstrated curative potential, the benefit of CAR-T cells and OVs as single-agent treatments remains limited to a subset of patients. Combinations of different targeted therapies may be required to achieve efficient, durable responses against heterogeneous tumors, as well as the microenvironment. Using a combinatorial approach to take advantage of the unique features of CAR-T cells and OVs with other treatments can produce additive therapeutic effects. This review also discusses ongoing clinical evaluations of these combination strategies for improved outcomes in treatment of resistant malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据